View ValuationAimed Bio 将来の成長Future 基準チェック /06現在、 Aimed Bioの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日18 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBuy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.分析記事 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.お知らせ • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South KoreaBuy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測KOSDAQ:A0009K0 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202654,1954,07412,33713,136N/A12/31/202547,2785,02317,49817,860N/A9/30/202520,706-22,751-1,121616N/A6/30/202520,705-19,982-6911,029N/A3/31/202513,221-354-7,034-5,388N/A12/31/202411,760-3,304-6,554-4,874N/A12/31/2023171-9,023-3,440-2,644N/A12/31/2022111-6,168-4,430-3,908N/Aアナリストによる今後の成長予測収入対貯蓄率: A0009K0の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A0009K0の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A0009K0の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A0009K0の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A0009K0の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A0009K0の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/27 07:17終値2026/06/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aimed Bio Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Keunhee SeoSamsung Securities Co. Ltd.
Buy Or Sell Opportunity • Jun 16Now 21% overvaluedOver the last 90 days, the stock has fallen 53% to ₩28,600. The fair value is estimated to be ₩23,679, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 76% per annum over the same time period.
分析記事 • May 25Investors Shouldn't Be Too Comfortable With Aimed Bio's (KOSDAQ:0009K0) EarningsInvestors were disappointed with Aimed Bio Inc.'s ( KOSDAQ:0009K0 ) earnings, despite the strong profit numbers. We did...
New Risk • May 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 33% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results.
Buy Or Sell Opportunity • May 20Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to ₩33,300. The fair value is estimated to be ₩41,769, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 24Now 26% overvaluedOver the last 90 days, the stock has fallen 5.5% to ₩50,200. The fair value is estimated to be ₩39,924, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 75% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 30% per annum. Earnings are also forecast to grow by 70% per annum over the same time period.
Buy Or Sell Opportunity • Apr 07Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to ₩45,300. The fair value is estimated to be ₩57,241, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 79% over the last 3 years. Earnings per share has declined by 30%.
お知らせ • Mar 13Aimed Bio Inc., Annual General Meeting, Mar 27, 2026Aimed Bio Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 9, jeongui-ro 8-gil, songpa-gu, seoul South Korea
Buy Or Sell Opportunity • Mar 04Now 31% undervaluedOver the last 90 days, the stock has risen 17% to ₩51,300. The fair value is estimated to be ₩73,923, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Buy Or Sell Opportunity • Jan 28Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at ₩57,200. The fair value is estimated to be ₩73,034, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has declined by 57%.
Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Inside Director Nam-Gu Her was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.